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StrokeSeveral guidelines recommend opportunistic screening for atrialﬁbrillation (AF) in subjects aged ≥65 years using
pulse palpation during routine blood pressure (BP) measurement. However, this method has limited diagnostic
accuracy. A speciﬁc algorithm for AF detection during automated BP measurement was developed and imple-
mented in a novel oscillometric device (MicrolifeWatchBPHome-A). In 2013, theUKNational Institute for Health
and Care Excellence (NICE) recommended this device for AF screening during routine ofﬁce BP measurement in
primary care in subjects ≥65 years. A review andmeta-analysis of the evidence on the diagnostic accuracy of this
algorithm were performed. Six studies (n = 2332) investigated the accuracy of AF detection using the Microlife
BPmonitor and estimated a pooled sensitivity at 0.98 (95% CI 0.95, 1.00) and speciﬁcity 0.92 (0.88, 0.96). Analysis
of 4 studies (n = 1126) showed more readings to improve speciﬁcity (from 0.86 to 0.91) and sensitivity (from
0.97 to 0.99). Taking 3 sequential readings with at least 2 detecting AF gave the highest diagnostic accuracy.
A single study (n= 139) of paroxysmal AF screening with home BP monitoring (3316 days) showed sensitivity
99% and speciﬁcity 93%. Another study (n = 46) of AF screening with 24 h ambulatory BP monitoring showed
that AF detected in N15% of all readings has high probability of AF diagnosis requiring conﬁrmation by 24 h elec-
trocardiography. AF detectionwith routine automated BPmeasurement is a reliable screening tool in the elderly,
which requires conﬁrmation by electrocardiography. Paroxysmal AF might also be detected by routine automated
home or ambulatory BP monitoring.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atrial ﬁbrillation (AF) is the most common sustained cardiac
arrhythmia and an important risk factor for stroke [1]. Its prevalence
is estimated at 1–2% of the general population [2,3] and increases
with age from 0.5% at 40–50 years to 5% in subjects over 65 years,
and 14% in those over 85 years [4,5]. However, there is evidence
that the true prevalence of AF is much higher [6,7]. The reasons
why AF frequently remains undetected are straightforward. Approx-
imately one third of people with AF have no clear symptoms [8,9],
and even in symptomatic cases, these are attributed to other rea-
sons. In addition, in case of paroxysmal AF (pxAF), episodes of the
arrhythmia may be of short duration and therefore difﬁcult to detect
[8]. These issues suggest the need of more extended and reliable AF
screening [10].rberk).
d Ltd. This is an open access article u2. Screening for AF
The importance of AF screening is increasingly recognized and
recommended by most cardiovascular societies [11–16] (Table 1).
Since hypertension is the most important risk factor of AF and showed
to affect up to 90% of the participants in AF trials [17], most guidelines
recommend pulse palpation to be performed in primary care clinics
during routine blood pressure (BP) measurement in patients aged
65 years and older; so-called opportunistic screening [18].
Pulse palpation, although inexpensive, has moderate diagnostic
accuracy with sensitivity and speciﬁcity values of 87 and 81%, res-
pectively [19]. The consequence of this low sensitivity might be an in-
crease in AF related morbidity and mortality. Moreover, low speciﬁcity
comes at high costs and an increased burden for health care. Due to
the low prevalence of AF of approximately 8% in subjects of 65 years
and older [19] low speciﬁcity leads to too many false positive ﬁndings.
Since patients in whom an arrhythmia is detected need to be referred
for a 12-lead electrocardiography (ECG) for conﬁrmation [18] (£31,
$46; prices NHS 2011) this comes at higher costs. The SAFE studynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Recommendations for screening of AF from scientiﬁc societies.
ESC 2012 [11] Opportunistic screening for AF in patients ≥65 years of age
using pulse-taking followed by an ECG is recommended.
AHA/ACC/HRS
2014 [12]
ECG documentation is recommended to establish the diagnosis
of AF.
CSS 2010 [13] It is incumbent upon the physician to document AF in at least
one ECG lead, when “irregularly irregular” palpations are
perceived.
AAN 2014 [14] In patients with cryptogenic stroke without known
non-valvular AF clinicians might obtain outpatient cardiac
rhythm studies, to identify patients with occult AF.
NICE 2014 [15] An ECG must be performed in all people, whether
symptomatic or not, in whom AF is suspected because an
irregular pulse has been detected.
NICE 2013 [16] WatchBP Home A should be considered for use in people with
suspected hypertension and those being screened or
monitored for hypertension, in primary care. People suspected
of having AF after use of WatchBP Home A should have an ECG.
AF, atrial ﬁbrillation; ESC, European Society of Cardiology; AHA, American Heart Associa-
tion; ACC, American College of Cardiology; HRS, Heart Rhythm Society; CSS, Canadian Car-
diovascular Society; AAN, American Association of Neurology; NICE, UK National Institute
of health and Care Excellence.
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ular pulse identiﬁed with palpation, was conﬁrmed as having AF [19].
Another practical problemwith pulse palpation as a screeningmeth-
od for AF during routine BPmeasurement in the ofﬁce is the fact that the
auscultatory BPmonitors (mercury and aneroid) are being progressive-
ly banned from clinical use and are usually replaced by automated elec-
tronic devices [20,21]. Unless the latter devices are able to automatically
detect AF, or a physical examination by the doctor is performed during
each visit (which is usually not the case in routine practice), there is a
risk that cases with asymptomatic AF might be missed during the clinic
visit. Thus, there is much room for improvement, which may be ac-
complished by replacing manual pulse palpation with a more accurate
technological innovation for AF screening.
Apart from the importance of the diagnostic accuracy of a screening
test (sensitivity, speciﬁcity), in the case of AF screening there is an addi-
tional issue due to patients having pxAF, which carries similar risk of
stroke as permanent AF. Thus, screening at multiple time points, e.g.
using 24-h Holter ECG, an event loop recorder (ELR) system or an im-
plantable cardiac monitor may signiﬁcantly improve AF detection [6,7,
22,23]. Indeed, the application of innovative devices in patients with
cryptogenic strokes demonstrated increased detection of AF by a factor
of more than ﬁve [6] and seven [7] compared to standard practice after
an extended screening period of 30 days and 3 years, respectively.
It is important to note that although the ECG certainly remains the
gold standard for AF diagnosis, this is very accurate only when carried
out by a specialist. This was clearly shown in a study that compared
the AF diagnosis made by general practitioners, and a computer software
algorithm using a 12-lead ECG, versus a reference diagnosis made by two
cardiologists [24]. The general practitioners' diagnosis proved to be im-
perfect with a sensitivity of 80% and speciﬁcity of 92%. When taking into
account the general practitioner's diagnosis together with the interpreta-
tive software (either or both positive), the diagnostic performance wasTable 2
Standard methods for atrial ﬁbrillation screening and diagnosis.
Method/trial N
Self-pulse palpation by trained patients [25] 4322
Pulse palpation during ofﬁce blood pressure measurement [19] 3278
12-lead ECG by General practitioner [24] 2595
12-lead ECG by General practitioner and interpretative software [24] 2595
One-lead ECG with auto-analysis [26] 1000
ECG, electrocardiography.improved, but only reached a sensitivity of 92% and speciﬁcity of 91%
[24]. The investigators concluded that many primary care professionals
cannot accurately detect AF on an ECG, evenwhen helped by an interpre-
tative software [24]. Self-diagnosis by patients of the pulse irregularity as
a screening test for the detection of AFhas been evaluated in a community
education programwith 4322 participants [25]. Unfortunately, 27% of the
trained participants could not ﬁnd their pulse, and of those who did, 9%
could not tell whether it was irregular [25]. Table 2 provides an overview
of the diagnostic results of several standardmethods for AF screening that
are used in clinical practice [19,24–26].
3. Arrhythmia detection during automated BP measurement
Several BP monitors with irregular heartbeat (IHB) detector (also
called arrhythmia detectors) are available on the market for a long
time. These devices generally have an algorithm which signals when
the heartbeat rhythm varies by more than 25% from the average heart-
beat detected during BPmeasurement [27]. A few clinical studies inves-
tigating the accuracy of IHB in detecting AF showed high speciﬁcity for
IHB but at a cost of low sensitivity [28–30] which led to the conclusion
that the IHB detector should not be used for AF screening [30].
The US Food and Drug Administration (FDA) has provided clearance
(otherwise known as a 510(k)) for several of these IHB detector BP
monitors. According to the FDA, speciﬁc manufacturer's claims should
be accompanied by respective and appropriate evidence [31]. In that
context it may seem strange that these IHB detecting monitors were
cleared without clinical evidence supporting the diagnostic accuracy
of the IHB detecting algorithm. The reason for this is because, according
to the FDA, an “irregular heartbeat detection feature” claim does not
present a “disease” diagnosis. The main purpose of the IHB detector,
therefore, is not to diagnose arrhythmias but rather to serve as a warn-
ingmessage indicating that the BP readingmay not be accurate because
of the presence of arrhythmia [32].
4. AF detection during automated BP measurement
An “AF detector” is considered to be a tool speciﬁc for AF screening.
In contradiction to “IHB”, the claim “AF” represents a disease diagnosis
according to the FDA. Therefore, its clinical application and performance
must be supported by adequate research evidence for obtaining FDA
clearance. The available clinical evidence for the AF detecting algorithm
resulted in the FDA clearance “by prescription” which means that rea-
sonable assurance of the device's safety and effectiveness for detecting
AF has been provided. The difference between IHB and AF becomes
straightforward with full understanding of both algorithms and their
purpose. However, in daily practice it appears that most consumers
and even clinicians do not recognize this difference. This not only
leads to confusion and misuse, but can also have important clinical
consequences when the IHB algorithm is used for AF screening [30]
since it is not designed and approved for this indication (Personal
communication).
There is only one algorithm for the evaluation of pulse irregularity
during automated BP measurement which has been speciﬁcally devel-
oped for AF detection (Microlife AG, Switzerland) [33]. The AF detectingAge
(years)
Outcome
N50 27% could not ﬁnd their pulse and of those who did,
9% could not tell whether it was irregular.
≥65 Sensitivity 87%, speciﬁcity 81%
≥65 Sensitivity 80%, speciﬁcity 92%
≥65 Sensitivity 92%, speciﬁcity 91%
≥75 Sensitivity 99%, speciﬁcity 87%
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requires veriﬁcation against ECG [26,34,35]. Since, the AF detector
operates independently of the BP measurement algorithm, it is not re-
stricted to a single device but can be implemented in other BPmonitors.
The AF detector functions as follows: the device measures the last 10
pulse intervals during cuff deﬂation and calculates the mean and stan-
dard deviation (SD) of the intervals. Each of the 10 pulse beat intervals
that is 25% longer or 25% shorter than the mean time interval is
discarded, in order to reduce the effect of premature beats. The re-
maining time intervals are used to calculate the irregularity index,
deﬁned as the SD divided by the mean of the time intervals [34]. If
the irregularity index exceeds a threshold value of 0.06 [34], an AF
symbol is displayed on the LCD screen of the monitor indicating
that the patient has AF [34,35].
To date, 6 published clinical trials investigated the diagnostic accura-
cy of AF detection with automated BP measurement [26,30,34–37]. All
these studies compared the results of the BP monitor against 12-lead
ECG interpreted by cardiologists and reported sensitivity, speciﬁcity
and accuracy values (Table 3).
The diagnostic accuracy of AF detection during automated BP
measurement depends on the number of readings obtained. Thus
the devices designed for ofﬁce or home use automatically perform
3 sequential BP measurements and provide the average BP value to-
gether with a yes/no report for AF presence. There are 3 reasons in
favor of triplicate BP measurement for AF detection. First, clinical
studies suggested that 3 measurements provide a better estimation
of a patient's true BP as compared to single measurements. Both the
AHA [38] and ESC [39] guidelines recommend taking at least two BP
measurements, and additional measurements if the ﬁrst two are
“quite different” [39] or differ by at least 5 mmHg [38]. Second, due to
the problematic estimation of BP in patients with AF, at least 3 sequen-
tial BP measurements are recommended [40]. Third, the diagnostic ac-
curacy of the AF detecting algorithm (sensitivity and speciﬁcity) is
improved with triplicate measurement [41].
Ameta-analysis of the 6 relevant studies (n=2332), as presented in
Table 3, was performed using “direct pooling” of aggregate-level data
for estimating sensitivity and speciﬁcity in AF detection [42]. Random
rather than ﬁxed effects models were performed as more appropriate
for balancing weights across large and small studies and to allow for
variation in study effects, due to the expected dispersion in the effect
size across studies. Meta-analysis was performed using the Stata/SE
11, Texas, USA software. Results were pooled weighted with inverse
variances. The analysis revealed pooled estimates for sensitivity at
0.98 (95% CI 0.95, 1.00) and for speciﬁcity 0.92 (95% CI 0.88, 0.96)
(Fig. 1). The required number of readings used for AF diagnosis was 2
out of 3 readings in 3 studies, 2 out of 2 in 1 study, and 3 out of 3 read-
ings in 2 studies (Table 3). Four studies provided comparative data onTable 3








Wiesel 2004 † [36] 450
Outpatients
69 53 (12) 1
2
Stergiou 2009 [35] 72
Outpatients
71 27 (37) 1
2
3




Wiesel 2014 [30] 199
Outpatients
74 30 (15) 1
3
Kearley 2014 [26] 999
Primary care
80 79 (8) 3
Gandolfo 2015 [37] 207
Stroke*
78 38 (18) 3
AF, atrial ﬁbrillation; ≠, Number of readings indicating AF which are required for AF diagnosis;
researchers as false negative; †, The Microlife AF detector was implemented in a different devithe diagnostic accuracy of a single reading versus 2 out of 2, or 2 out
of 3 readings in terms of sensitivity and speciﬁcity. By using a larger
number of readings, a small improvement was achieved in sensitivity
(from 0.97, 95% CI 0.93, 1.00 to 0.99, 95% CI 0.97, 1.00; Fig. 2) and in
speciﬁcity (from 0.86, 95% CI 0.84, 0.89 to 0.91, 95% CI 0.89, 0.93; Fig. 3).
In the studies of the diagnostic accuracy, two different protocols
have been used to deﬁne the AF diagnosis after taking 3 sequential BP
readings: the so-called “majority rule” (2 of 3 readings should be AF
positive to deﬁne AF) and the “3 out of 3 rule” (all 3 readings should
be AF positive). The majority rule appears to lead to higher sensitivity
at a cost of lower speciﬁcity compared to the 3 out of 3 rule. More spe-
ciﬁcally, the pooled sensitivity and speciﬁcity for the 3 studies (n =
676) using the “majority rule” were 0.98 (95% CI 0.95, 1.00) and 0.90
(95% 0.87, 0.93) respectively, whereas the respective values for the 2
studies (n = 1206) using the “3 out of 3 rule” were 0.94 (95% CI 0.88,
0.99) and 0.95 (95% CI 0.86, 1.00).
The majority rule appears to be more suitable for the clinic setting
whereas the “3 out of 3” rule is probably more appropriate for long-
term homemonitoring. This is because in the clinic setting the number
of visits and the opportunity to screen for AF are limited to a few times a
year, so that a higher sensitivity would be required to compensate for
the risk ofmissingAF. On the other hand, at home,wheremore frequent
measurements are routinely taken, the chance of detecting AF is much
higher. In addition, false positive readings can induce anxiety, which
can be lessened by applying a measurement protocol with higher
speciﬁcity.
5. Indications for AF screening with automated BP measurement
Opportunistic screening, i.e. pulse palpation in patients 65 years and
older during a general practitioner (GP) consultation for any reason,
followed by an ECG in case of irregularity, is the recommended screen-
ing method according to the guidelines of the European Society of Car-
diology [3]. Opportunistic screening appears to be more effective than
routine practice (OR 1.57, 95% CI 1.08 to 2.26) and less costly than sys-
tematic screening [43]. The effectiveness of screening in people younger
than 65 years of age is thought to be low because of the low prevalence
of AF in this population. Studies investigating the effect of screening in
younger age groups are lacking and caution needs to be taken when ex-
trapolating the results of screening studies from older to younger sub-
jects [43]. However, screening for AF in very young patients has been
shown to be problematic due to many false positive ﬁndings related to
the high prevalence of sinus arrhythmia. Since the prevalence of AF
for those younger than 55 years of age is estimated at 0.1% [44], screen-
ing for AF in younger subjects is not recommended. Another reason not
to screen for AF in a young healthy population would be that this popu-









1 1.00 (0.97–1.00) 0.84 (0.81–0.86) 86
2 1.00 (0.94–1.00) 0.92 (0.87–0.93) 92
1 0.93 (0.74–0.99) 0.89 (0.76–0.96) 90
1 1.00 (0.84–1.00) 0.76 (0.60–0.87) 85
2 1.00 (0.84–1.00) 0.89 (0.75–0.96) 93
1 0.95 (0.93–0.98) 0.86 (0.84–0.89) 87
2 0.97 (0.91–0.99) 0.89 (0.85–0.92) 91
1 0.97 (0.81–1.00) 0.90 (0.84–0.94) 91
2 1.00 (0.86–1.00) 0.92 (0.86–0.96) 93
3 0.95 (0.88–0.99) 0.90 (0.88–0.92) 90
3 0.89 (0.77–0.96) 0.99 (0.96–1.00) 97
*, 4 subjects had atrial ﬂutter which the device detected as AF and were considered by the
ce.
Fig. 1. Forest plot of pooled estimates for sensitivity (A) and speciﬁcity (B) of AF diagnosis with automated BP measurement.
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agents in case of AF [45].
Although the AF detector during automated BP measurement
appears to be modestly capable to distinguish AF from several
other arrhythmias, the chance of false positive ﬁndings may be in-
creased in the presence of multiple premature ventricular (speci-
ﬁcity 62%) or atrial (43%) beats and also with sinus arrhythmia.Therefore, the oscillometric BP monitor with AF detector is not
suitable for use in children [46] or pregnancy because in these
cases sinus arrhythmia is common [47,48].
It may be considered also appropriate to screen patients aged
N50 years with cardiovascular risk factors because, as compared to the
general population, diabetes leads to a 1.4- and 1.6-fold (men and
women) risk, and hypertension to a 1.5- and 1.4-fold risk for developing
Fig. 2. Forest plot of pooled estimates for sensitivity of AF diagnosis with automated BP measurement by using a single (A) or more than one reading (B).
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tion for these high-risk subjects.
6. AF detection during automated out-of-ofﬁce BP monitoring
Since AF is often asymptomatic or paroxysmal, the potential of
screening the elderly hypertensives in multiple occasions out of
the ofﬁce during routine BP monitoring appears challenging. Bothself-home and 24-h ambulatory monitoring offer the opportunity
of repeated evaluation for AF in the usual environment of each
individual.
Subjects suspected of having pxAF (e.g. those with transient ische-
mic attack or minor stroke), are evaluated with 24–48 h ECG (Holter),
which might be followed by an ELR system for several weeks [6,22,
23]. The disadvantage of the ELR is that it is costly, mainly due to the
need of a technician and data transmission [50]. AF detection during
Fig. 3. Forest plot of pooled estimates for speciﬁcity of AF diagnosis with automated BP measurement by using a single (A) or more than one reading (B).
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patients at home has the advantage that it can be widely used in the
population to screen for AF andmay be amore cost effective alternative
to the current screening approach.When considering that hypertension
is themost important cardiovascular risk factor for AF [49] and approx-
imately 80% of AF patients have hypertension [17], it is expected that
many patients at high risk for AF already have hypertension and are fa-
miliar with self-home BP monitoring. AF detection with automated BP
measurement at home has been compared against ELR for detectingpxAF in a population of 139 outpatients (14 with known AF) at risk of
stroke aged 65 years and older with hypertension [51]. Participants
measured themselves daily at home using the BP monitor with AF
detection and these readings were compared with ELR. At the end of
the study there was a total of 3316 days with BP monitor readings and
ELR. On the basis of the daily BP measurements, the BP monitor
demonstrated sensitivity of 99% and speciﬁcity of 93% for detecting
AF. In addition, two subjects with no histories of AF were detected
with the BP monitor [51].
Table 4
Recommendations for AF detection with automated BP measurement.
Measurement Recommendation
Ofﬁce BP • Indicated for AF screening in subjects aged ≥65 years (NICE).
No evidence for indication for younger subjects
• Obtain 3 consecutive BP measurements. If ≥2 suggest AF, the
diagnosis is highly possible and should be conﬁrmed by ECG.
Home BP • Long-term self-monitoring of BP by elderly hypertensives
might allow early detection of asymptomatic AF.
• Repeated monitoring might identify paroxysmal AF.
Ambulatory BP • Might detect paroxysmal AF during routine evaluation of BP
in elderly hypertensives.
• Preliminary results suggest that AF detected in N15% of 24 h
readings has high probability of AF diagnosis and requires
conﬁrmation by ECG.
AF, atrial ﬁbrillation; BP, blood pressure; ECG, electrocardiography; NICE, UK National
Institute of health and Care Excellence 2013 [16].
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cost-effective than ofﬁce BP measurement for diagnosing hypertension
[52]. Several guidelines recommend ambulatory monitoring for
conﬁrming the ofﬁce BP elevation [16,39] and the UK National Institute
for Health and Care Excellence (NICE) guidelines have recommended
this method for all subjects with suspected hypertension [18]. Conse-
quently, an increasing number of patients are evaluatedwith ambulato-
ry BP monitoring in routine clinical practice.
The AF detecting algorithm has been implemented in an ambulatory
BPmonitor (WatchBP O3 AF, Microlife AG) aiming to facilitate the iden-
tiﬁcation of pxAF. A preliminary study investigated 46 elderly hyperten-
sives with simultaneous 24-h ambulatory BPwith AF detector and 24-h
ECG (Holter) [53]. In those with permanent AF on average 5.1± 2.5% of
all BP measurements were false negative, and in those with sinus
rhythm7.3±8.2% of the readingswere false positive for AF. Onepatient
with history of minor stroke and sinus rhythm in the ofﬁce was diag-
nosed with pxAF conﬁrmed by both the Holter ECG and the ambulatory
BP device. Seven non-AF subjects had N15% of their BP readings with
false positive AF (mean 33 ± 17%). One of them had constant Mobitz I
atrioventricular block, whereas in the others the main arrhythmia was
frequent supraventricular premature beats, mainly in the form of cou-
plets. In a reading-to-reading analysis compared to ECG, sensitivity
and speciﬁcity in diagnosing AFwere 91% and 85% respectively (unpub-
lished data). The authors suggested that a threshold of N15% AF positive
readings might be proposed to require 24-h Holter ECG recording for
conﬁrming AF or other important arrhythmias. However, these results
are preliminary and more research to deﬁne the optimal diagnostic ap-
proach based on ambulatory BP monitoring is required.
7. Automated BP measurement accuracy during AF
Whether BP can be measured accurately with an oscillometric
device in patients with AF is still a matter of debate [40,54,55]. A
meta-analysis of rather heterogeneous trials demonstrated that
the oscillometric devices are relatively accurate in measuring systol-
ic but not diastolic BP [56]. However, this meta-analysis is based on
comparisons to manual BP measurement which is also prone to er-
rors in the presence of AF [57]. Pagonas et al. performed a cross-
sectional study in 102 patients (50 with AF) to assess the accuracy
of oscillometric BP measurement as compared to invasive BP measure-
ment and showed that both systolic and diastolic BP values (mean of 3
readings) did not signiﬁcantly differ in the presence or absence of AF
[57]. The authors concluded that the current guidelines recommending
repeated BP measurements using sphygmomanometry in AF may also
apply to oscillometry.
8. UK NICE recommendation on AF detection with automated BP
measurement
The UK NICE which provides guidance for medical decisions in the
National Health Service (NHS), has implemented a Medical Technologies
Guidance programme (MTG) [58], which evaluates innovative medical
technologies aiming to assist the NHS in adopting efﬁcient and cost effec-
tive medical devices and diagnostics more rapidly and consistently. In
2013 the NICE recommended the automated oscillometric BP monitor
WatchBP Home A (Microlife AG, Widnau, Switzerland) for routine ofﬁce
BP measurement in patients aged 65 years and older in primary care
[16,59]. It is important to note that this indication by the NICE is speciﬁc
to the Microlife WatchBP AF detecting algorithm and does not apply to
any other arrhythmia detector implemented in BP monitors [16,59].
Given the high diagnostic accuracy of the AF detector as shown in the
abovementioned clinical studies (sensitivity and speciﬁcity 90–100%
[26,30,34,37]), theNICE anticipates that thiswill lead to stroke prevention
(between 53 and 117 fewer fatal strokes, and 28 and 65 fewer nonfatal
strokes) and cost savings due to lower hospital costs for stroke treatment(£2.98 [$4.77 for subjects aged 65–75 years] and £4.26 [$6.82, for those
≥75 years] [60].
A recent study by Kearley et al. assessed the performance of the
WatchBP Home A and two single-lead ECG devices, as diagnostic triage
tests for the detection of AF among 1000 ambulatory patients aged
≥75 years from 6 General Practices in the UK (AF prevalence 7.9%)
[26]. As compared against the reference standard (12-lead ECG, inde-
pendently interpreted by cardiologists) all three devices had a high sen-
sitivity (93.9–98.7%) and are thus useful for ruling out AF. However, the
authors concluded thatWatchBP is a better triage test thanOmron auto-
analysis because it is more speciﬁc; 89.7% (95% CI 87.5% to 91.6%) com-
pared to 78.3% (95% CI 73.0% to 82.9%), respectively. Because this
would translate into lower ECG referral the authors supported the
NICE recommendation and conﬁrmed the usefulness of the WatchBP
Home A monitor in primary care [26].
9. Conclusion
Screening for AF in primary care is recommended for subjects aged
65 years and older. AF detection during automated BP measurement is
feasible in primary care and appears to be superior to pulse palpation
in terms of diagnostic accuracy for AF, and might be more accurate
and cost-effective than 12-lead ECG by general practitioners. The AF de-
tector differs from all other arrhythmia detectors implemented inmany
automated BPmonitors in that it is speciﬁc for AF. The other arrhythmia
detectors are rather warning signals that the BP measurement may not
be accurate, than to diagnose arrhythmias. AF detection during auto-
mated BP measurement in clinical practice should be applied as follows
(Table 4): Screening for AF is indicated in subjects aged 65 years and
older. In younger subjects currently this is not recommended due
to lack of evidence and increased prevalence of false positive results
induced by sinus arrhythmia. Three sequential measurements
should be taken and AF diagnosis should be conﬁrmed by ECG. In
suspected pxAF, repeated automated home BP monitoring with AF
detector may be considered to increase the chance of AF diagnosis.
AF detection during routine ambulatory BP monitoring in elderly
hypertensives who are at increased AF risk might identify asymp-
tomatic or paroxysmal AF.
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